RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 461 full-time employees. The company went IPO on 2021-07-30. The firm's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
Dr. Ron Kurtz 2016 'den beri şirketle birlikte olan Rxsight Inc 'in President 'ıdır.
RXST hissesinin fiyat performansı nasıl?
RXST 'in mevcut fiyatı $6.39 'dir, son işlem günde 0% 감소된 etti.
Rxsight Inc için ana iş temaları veya sektörler nelerdir?
Rxsight Inc Health Care endüstrisine ait ve sektör Health Care 'dir
Rxsight Inc 'in piyasa değerlemesi nedir?
Rxsight Inc 'in mevcut piyasa değerlemesi $263.7M 'dir
Rxsight Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 11 analist Rxsight Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 0 güçlü al, 1 al, 10 tut, 3 sat ve 0 güçlü sat içermektedir